IL174260A0 - Quinazoline derivatives as antitumor agents - Google Patents

Quinazoline derivatives as antitumor agents

Info

Publication number
IL174260A0
IL174260A0 IL174260A IL17426006A IL174260A0 IL 174260 A0 IL174260 A0 IL 174260A0 IL 174260 A IL174260 A IL 174260A IL 17426006 A IL17426006 A IL 17426006A IL 174260 A0 IL174260 A0 IL 174260A0
Authority
IL
Israel
Prior art keywords
antitumor agents
quinazoline derivatives
quinazoline
derivatives
antitumor
Prior art date
Application number
IL174260A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Hennequin Laurent Francois Andre
Bradbury Robert Hugh
Kettle Jason Grant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL174260(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Hennequin Laurent Francois Andre, Bradbury Robert Hugh, Kettle Jason Grant filed Critical Astrazeneca Ab
Publication of IL174260A0 publication Critical patent/IL174260A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL174260A 2003-09-16 2006-03-12 Quinazoline derivatives as antitumor agents IL174260A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321648.8A GB0321648D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives
PCT/GB2004/003936 WO2005026152A1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
IL174260A0 true IL174260A0 (en) 2006-08-01

Family

ID=29227164

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174260A IL174260A0 (en) 2003-09-16 2006-03-12 Quinazoline derivatives as antitumor agents

Country Status (17)

Country Link
US (1) US20070015743A1 (cg-RX-API-DMAC7.html)
EP (1) EP1664029B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007505874A (cg-RX-API-DMAC7.html)
CN (1) CN1882572A (cg-RX-API-DMAC7.html)
AR (1) AR045752A1 (cg-RX-API-DMAC7.html)
AT (1) ATE450528T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004272351A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414486A (cg-RX-API-DMAC7.html)
CA (1) CA2539024A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024420D1 (cg-RX-API-DMAC7.html)
GB (1) GB0321648D0 (cg-RX-API-DMAC7.html)
IL (1) IL174260A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002965A (cg-RX-API-DMAC7.html)
NO (1) NO20061320L (cg-RX-API-DMAC7.html)
TW (1) TW200526628A (cg-RX-API-DMAC7.html)
WO (1) WO2005026152A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602189B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231230D1 (de) * 2001-11-03 2009-04-02 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
KR20070027487A (ko) * 2003-09-16 2007-03-09 아스트라제네카 아베 퀴나졸린 유도체
BRPI0414489A8 (pt) * 2003-09-16 2019-01-15 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
WO2005026156A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005075439A1 (en) * 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物
DE602005026865D1 (de) * 2004-12-14 2011-04-21 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
KR20080027253A (ko) * 2005-06-16 2008-03-26 미리어드 제네틱스, 인크. 약제학적 조성물 및 이의 용도
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
WO2007059257A2 (en) * 2005-11-15 2007-05-24 Array Biopharma Inc. N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
EP1960371B1 (en) * 2005-12-02 2009-09-16 AstraZeneca AB Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
US20100222344A1 (en) * 2005-12-02 2010-09-02 Astrazeneca Ab 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
BRPI0807234A2 (pt) 2007-02-06 2014-06-03 Boehringer Ingelheim Int Heterociclos bicíclicos, composições farmacêuticas que contêm estes compostos, o uso dos mesmos e processos para a preparação dos mesmos
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
JP2010523696A (ja) * 2007-04-10 2010-07-15 ミリアド ファーマシューティカルズ， インコーポレイテッド 脳腫瘍を治療する方法
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
MY183041A (en) 2008-05-13 2021-02-08 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2852060A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
CA2852058C (en) 2011-10-14 2021-06-01 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
AR117424A1 (es) * 2018-05-08 2021-08-04 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de los receptores erbb

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6117433A (en) * 1996-01-31 2000-09-12 Dsm N.V. Use of compositions comprising stabilized biologically effective compounds
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6148197A (en) * 1998-03-06 2000-11-14 Sbc Technology Resources, Inc. Intelligent roaming system with over the air programming
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
IL144143A0 (en) * 1999-02-27 2002-05-23 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
DE60231230D1 (de) * 2001-11-03 2009-04-02 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1660479A1 (en) * 2003-07-29 2006-05-31 Astrazeneca AB Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
KR20070027487A (ko) * 2003-09-16 2007-03-09 아스트라제네카 아베 퀴나졸린 유도체
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0414489A8 (pt) * 2003-09-16 2019-01-15 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
ATE353888T1 (de) * 2003-09-19 2007-03-15 Astrazeneca Ab Chinazolinderivate
CA2540008A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005075439A1 (en) * 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物

Also Published As

Publication number Publication date
MXPA06002965A (es) 2006-06-14
EP1664029A1 (en) 2006-06-07
AR045752A1 (es) 2005-11-09
DE602004024420D1 (de) 2010-01-14
GB0321648D0 (en) 2003-10-15
US20070015743A1 (en) 2007-01-18
AU2004272351A1 (en) 2005-03-24
WO2005026152A1 (en) 2005-03-24
CN1882572A (zh) 2006-12-20
ZA200602189B (en) 2007-11-28
JP2007505874A (ja) 2007-03-15
CA2539024A1 (en) 2005-03-24
BRPI0414486A (pt) 2006-11-14
ATE450528T1 (de) 2009-12-15
EP1664029B1 (en) 2009-12-02
NO20061320L (no) 2006-04-26
TW200526628A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
IL174260A0 (en) Quinazoline derivatives as antitumor agents
GB0322409D0 (en) Quinazoline derivatives
IL174534A0 (en) Quinazoline derivatives
IL161619A0 (en) Quinazoline derivatives as antitumor agents
IL161620A0 (en) Quinazoline derivatives as antitumor agents
ZA200602264B (en) Quinazoline derivatives
IL174257A0 (en) Quinazoline derivatives
IL233046A0 (en) Quinazoline macrocyclic derivatives as antiproliferative agents
GB0215823D0 (en) Quinazoline derivatives
PT1847539E (pt) Derivados de quinazolina
PL378245A1 (pl) Pochodne pirolopirydazyny
IL174390A0 (en) Quinazoline derivatives
IL175421A0 (en) Quinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
GB2410025B (en) Quinazolin-4-one derivatives
GB0321621D0 (en) Quinazoline derivatives
PL374817A1 (en) Quinazoline derivatives
GB0321620D0 (en) Quinazoline derivatives
HK1091490A (en) Quinazoline derivatives as antitumor agents
GB0322458D0 (en) Quinazoline derivatives
GB0322410D0 (en) Quinazoline derivatives
GB0322536D0 (en) Quinazoline derivatives
GB0309870D0 (en) Quinazoline derivatives
GB0322535D0 (en) Quinazoline derivatives
GB0322534D0 (en) Quinazoline derivatives